All right. Good morning, everybody. Welcome to today's session. My name is James Vane-Tempest. I am Jefferies European Specialty Pharma Analyst. Delighted to welcome Sandoz for this fireside chat session. We have Richard Saynor, the CEO. Richard, thank you very much for joining us. Maybe just to start with, perhaps you can, for people who maybe are not as familiar with the business, give us a few key highlights from your recent CMD, and also the site tours in Slovenia, which I guess I had the pleasure of attending last week. That is obviously clearly to support your Bio100 strategy.
Yeah.
Lead with that, and then we will jump into some questions. Thank you.
Yeah. Thank you, James. It is a rogue's gallery of the generics industry here today. It is slightly intimidating. Look, we had the CMD, what, two months ago now. Used that as an opportunity to really reframe the expectation. In the last 20 years, we have launched 13 biosimilars. In the next 15, we are going to launch 40 or 50, continue that acceleration. It also outlined the plans in terms of how we are investing. Again, one of the things that I believe differentiates Sandoz, vertically integrated. I always joke I could run off into the sunset with Armin and set up a biologics company by in-licensing, but I do not think that makes you a biosimilar company. Being vertically integrated and having that and the capability. Then I think the most important, which I know is slightly counterintuitive, is the competitive intensity landscape is going down, not going up.
As you see potentially about 100 biologics losing their LOE over the next 10 years, what we actually see from the IQVIA data and from our own experience is that the number of competitors per asset is going down, even though at first glance you see some of the regulatory hurdles being removed. So we see a landscape with, what, nearly $400 billion of LOE in biologics coming off patent over the next 10+ years. We already have a global share of about 20%. We would aspire to get that north of 30%, 35% over the next 10 years. I think we are uniquely positioned to leverage and build on that capability. Then the Slovenia visit, clearly then this is an execution journey. It was an opportunity to show some of our investors and the analysts our facility in Slovenia there.
We have both small fed-batch, large fed-batch, development, fill-finish. We had a great attendance. I think you met the President of Slovenia, which is nice. I always joke if we had done that in Germany, I very much doubt that Merz would have shown up. Again, it just shows the level of commitment that we are getting both from the Slovenian government, but also from our own organization. So very, very proud that you could see it. Happy to take your questions.
Thank you. I think when you gave the CMD at the time of the spin, with the mid-single-digit growth, you updated that looking from 2025 to 2030. Mid to high, mathematically, it seems that the growth is going to be accelerating towards the end of the decade, and you have talked about double-digit growth in 2030. A lot of the questions I get from investors is, I guess, what gives you the confidence in that with the visibility that you have when it is hard to predict, I guess, competitor behavior, regulators, et cetera? So to kind of give us the building blocks, how that is going to come together in the context that you can.
Sure. Do you want me to start from 2027 and work and build?
Yeah, I think that would be useful.
Okay. I think 2027, pretty much all of the building blocks in place for next year. We've got a number of I mean, I think one of the things we perhaps did, or we've confused people, is people see the LOE charts. That's not necessarily a launch plan. It's when the first market loses exclusivity. If you look at 2027, we've got a number of launches, insulins, a whole bunch of stuff that we're launching into Europe. We just signed a deal for aflibercept in the U.S., which I'm super excited about. That sort of kicks in in the last second half of 2027. Strong growth driver then into 2028. We're launching four biosimilars in Japan next year. Japan is the third-largest biosimilar market in the world. We have a strong partnership in Brazil with the government doing PDP.
You've got a number of opportunities as we continue, and the base business continues to grow. I think last quarter we grew our biosimilar business 17%. You see strong underlying growth, still a significant number of launches. They flow into 2028. As you then get into 2029, there's a number of other launches. No one ever talks about Enbrel or etanercept. That's one of the biggest LOEs still. We launched that in the U.S. in 2029, yet no one ever mentions it, but we launched that in Europe, I think, 10 years ago. It'll be 13 years from first launch to peak sales. Number of things, I'm excited. Then clearly as you get into the 2029s, into 2030s, pembro, and then a number of assets start flowing through that continue to accelerate the growth beyond that.
2027, I think everything now is approved other than I think one asset where we're currently in court in small molecules, which isn't built in our assumptions anyway, that's an exciting opportunity. Then clearly you've got GLPs, you've got a whole bunch of other stuff going on.
I think part of the strategy investors are focused on is the increasing vertical integration of the company. Seeing actually Slovenia and then Lendava was a great opportunity to see how that capacity's being built out. Can you kind of help us understand how the phasing of either that's expected to ramp up the additional capacity that that site can essentially do, to hopefully then capture more of the economics yourself rather than use partners?
Yeah, sure. As you saw, the large fed-batch capacity of 120,000 l, we can expand it relatively easily. We've over-engineered the facility and the land to do that. Clearly our priority now, the site's finished, and we're now through the regulatory phases. We'll get that on stream, and Armin's here, so that's all tracking nicely. Then clearly we take a lot of our supply from our old parent. That's a good relationship. We can then choose either to tech transfer that capacity out or continue with some of that capacity coming through from Novartis. I think it'd be logical to keep that balance anyway, so we have flexibility. Then as you get to 2029, then we'll start pulling more and more of the volume from our own network.
Our goal by 2035 is at least 60% of our volume would come from our own network, from a vertical integrated supply chain, and we're also on track. Then the other piece, which is important, is we also have two other technology platforms. We have small fed-batch in Ljubljana. Really, the difference is a decision in terms of yield. Small fed-batch will give you, I guess, tens of kilos of product, and large fed-batch, hundreds of kilos, tons of product. Clearly, having the choice between the two means that you can optimize your supply chain. Then in the middle of that, we have continuous manufacturing, which is more designed for the middle yield.
Then I'm almost always reminded of the Thomas Strüngmann story when he told me, "Look, you only need to know three things to run a generics company. Be the cheapest, be the first, and be the most flexible." The problem is that managing the interface between all three of those. Owning your own supply chain means that we can make trade-off choices when we need more capacity in a particular product, build more flexibility. Having that dynamic is absolutely key.
You guide at the EBITDA level, and I think a question I often get from investors as well is, with a lot of the launches via partners over the next few years, I appreciate every deal structure is different.
But, on the one hand, is there, if there are gross margin pay-aways, but then there's less development costs associated with it, how should we think about launches from partners, at least until your own development pipeline sort of picks up, constraining some of the gross margin expansion that could come from your own side over time? Or does that not apply?
Well, clearly, a partner product is less profitable than a fully vertically integrated, but on generally, most are more profitable than a classic simple small molecule. So, it's accretive to the business anyway. Then you think about it in waves as we then bring our own capacity on stream on the existing volume. There's opportunities then to improve our cost of goods by not paying someone else to make it for you. There's opportunities to expand existing products, a product like erythropoietin, where we have one of the leading shares in Europe. We're massively more demand than we have supply. As we de-bottleneck that and bring more capacity, it's extremely profitable, next to no SG&A to support it, and can clearly add value. So there's opportunities along the way there.
We're still evolving as an organization, so the way we manage the business, clearly we expect the growth, and I won't get into guidance next year, but from a business point of view, we try and hold the SG&A flat, so that then drives leverage. There's still procurement opportunities, there's still operational efficiencies. We have a lot of capabilities that we've built in locations like India to run a lot of our backend services, and that's still ongoing. So, I think you've got a number of levers. We've consistently said, "Look, we would improve our EBITDA delivery year on year by probably about a percentage point, getting to around 30% by 2035.
Yep
That journey's on track. This year, we raised our guidance again because we saw stronger demand in biosimilars, perhaps a little bit more than we anticipated, but again, it shows how the strategy's working in terms of leveraging that and bringing it through to the bottom line.
When you talk about the business model still evolving, you want to take the number of in-house candidates from two to seven.
What are the limitations in order to get there quicker? Is it capital? Is it people? Is it pipeline planning? Some investors wonder, that evolution over time, is it a quality metric, for example? What would it take to get to seven quicker than what you anticipate?
Armin's here, so I'm pushing him to accelerate that as hard and as quick. I mean, it's people and execution, but now the facilities are built. I mean, you saw the facility in Ljubljana. We have another facility in Munich. We will continue to expand the number of assets. But again, you've got to remember that most of those assets aren't going to be launched until the middle of the 2030s. So it's a balance between accelerating the short-term pipeline and not missing opportunities with the right strategic partners, and then accelerating our own pipeline of in-house. I guess we're lucky that we have the choice. A lot of our competitors don't have that choice.
Yeah.
We would see ourselves as a partner of choice to leverage that, but equally then think about how we expand it over time.
Bio100 as an ambition is much bolder than some of your competitors. I guess another question we get as well is, you are targeting the 80% LOE coverage, but how do you avoid a small, smaller products, a long tail, a less profitable products? Just to understand the mix.
I would turn it around. I mean, I would love a $300 million product with no competition, that ticks along at 90% gross margin. I do not think you end up with a sad, highly diluted, long biologics tail. I think what we have seen is products like EPO, look at human growth hormone, look at those things. Is anyone ever going to develop a biosimilar to human growth hormone again, or erythropoietin? I do not think so. Unlike small molecules, I take your point, but I think biologics do not decay in the same way. Patients' needs, I think, have a huge opportunity. I got told this morning that $100 million was not ambitious enough. I said, "Okay, I have got to go back to the drawing board, Rebecca. We need more products.
Yeah
I do not know. If anything, I would see it more as a positive rather than a negative.
I guess the other side of that, as you move into more complex modalities such as ADCs, do you have all those capabilities or are there additional investments that are required?
We have those capabilities. I mean, that's one of the reasons Armin's here. Clearly, we're a small molecule company and we're a biologics company, and we have that capability, or we can choose to work with partners to do that. Clearly, we're developing ADCs and we've disclosed that. We see nice opportunities there, also bispecifics, trispecifics.
M&A is also an option, and I think you've got a targeted leverage of less than 2x. You've got this increasing dividends policy to 30%-
Yeah
40% over time. How much capacity is there for further large BD, and I guess what type of deals would you be after?
I mean, we're fortunate in a way, as we sit here, I'm not sure what would make a sensible. I think we've done some deals. Obviously, we did the Evotec deal to give us capacity in Toulouse. There's some probably smaller incremental things that we could do, but transformational, I think we have a clear strategy, we have the balance sheet, we have the momentum. I think it would be distracting to the organization, and I'm not sure it would necessarily be value accretive.
Yeah
I think we always said, certainly when we spun the company, M&A was not top of our priorities, certainly for the next four or five years, as we build the company, get the momentum back, strengthen the balance sheet.
Bringing things to the more shorter term, I think at Q3, I think some investors were surprised about the German reform impact.
I think some of the longer-term, say, bears of the industry would worry that you see long-term commoditization in biosimilars, that you see this kind of price erosion. I think people seeing that were potentially worried, is this the start of something more longer term? Can you put what happened in Q3 in context, I guess what gives you-
Yeah, sure. I mean, I also argue, biologics are commodities. I am not going to sugarcoat it. They are biosimilar. You are selling a product on its similarity to something else. I do not think there should be any confusion in that. I think the difference is, in Germany, we saw a big uptake in volume, but clearly what happened is the sick funds moved to open house contracts, open house tenders. A lot of Europe already, if you look in the Nordics, look in the U.K., you look at France, already have those models, so it is not a change. What happened is then you saw more uptake, more penetration. So we saw a volume increase linked to tender. Pricing in the tender is down to the level of competition and the willingness of those tender players to participate at a price.
In the medium long term, I think that's a good thing. It means we get more leverage, which means we get much more access, more volume more quickly, and pricing is a function of the level of competition. I would argue globally having a 20% share, and in Germany, we're by far the largest player, we're in a very strong position to leverage that. I think the challenge we had is that volume ran ahead of our forecast.
Yeah.
So your ability to match that demand in the short term. As we go to 2027, we have secured more than enough volume to meet the forecast we put in the financial plan. I can't comment if a competitor goes out of stock or something dynamic happens in the market, but in terms of our confidence to deliver the volumes needed to deliver what we believe is the right number.
Outside of Germany, when you have conversations with other European payers, what sort of feedback do you get from them in terms of their willingness to either pay and support, or is it always I know the generics industry, I've looked at it well myself, is there's always those kind of challenges, but I guess given the cost savings, what's the appetite?
Huge. I mean, look, I was-
On price.
I mean, look at North America alone. We could say, with a Bio100, we could save a trillion dollars out of North America in healthcare costs over the next 10 years. Unless you are Elon Musk, that is a big number.
Yeah.
We have great access to the White House and to the I am in Downing Street tomorrow. We have great access to government in terms of, okay, how do we set policies to drive savings? Because there is $600 billion of product coming off patent in the next 10 years. That is huge savings. In the U.K. alone, that is probably $50 billion of savings that we could bring, not just to Sandoz, but as an industry.
Investors get the volume argument, but I guess it is the pricing argument. I think-
Well, pricing is always a function. It is a function of competition. In very few markets, the government set the price. The price has always been set by the level of competition. Going back to my opening statement, do I think the level of competition, particularly in biologics, is going to go down? It is not going to go up, because you have 100 products, it is still three to five years, it is still $100 million, you still need a capacity, you still need IP, you still need 100 markets capable of selling this stuff, and every one is different. The barriers to entry, so unless you started five years ago, it is too late. It is very, very hard. So, we are part of the solution.
Yeah.
But I see a really strong position, and that is why I go back to the 20% market share for Sandoz going to 30%-35%, versus a 4% in terms of small molecule commodity generics.
Yeah. Maybe I will ask you a different question then around pricing. I think the industry has tried to make some inroads on value-added medicines, for example, and I know we have spoken about this before where I guess there is no desire to go into value-added medicines. But if you see European governments willing to pay for innovation, is that something, A, you would consider, and B, how likely do you think it would be to potentially capture some value there?
Yeah. I have spoken to a lot of governments across Europe. I mean, I still believe value-added medicines are a solution to a problem no one wants to pay for. My opinion has not changed. I think, yes, there is always the slightly better mousetrap, but I just do not see it. I think if we were sitting here saying, "Well, there is no more potential, no more opportunity," but let us be real, in the next 10 years, there are more products coming off patent than in the history of this industry, and we are uniquely positioned to capture a significant proportion of that, which is why I described this as Sandoz's golden decade. So, I do not want to distract the organization by value-added medicines or digital therapeutics or whatever. No, there is so much.
This is an execution journey, and I want the organization absolutely laser-focused on being the absolute best biosimilar and generics company you can possibly be. I think trying to confuse it by value-added medicines or biobetters or all of that stuff.
Yeah. If this is an execution journey, and I guess there is a lot of opportunity that you've laid out, what's the greatest risk of that execution in terms of priority and focus, developing assets? If we were to sit here for five years' time, for whatever reason, you haven't delivered on that ambition, what do you think the reasons could be?
I think it's not one thing. I think we've got a site built now in Slovenia. We've got to get it through the regulators. We've got a significant number of files, but our confidence about getting those through are high. It's not one thing that's got to happen. You could argue there's 100 things that have got to happen. If 80 work and 20 don't, it doesn't change the fundamentals of the business. I mean, clearly you've got other geopolitical, but okay, we're well-positioned in Europe. We have a strong home base. The world's getting sicker, the world's getting older, the world's getting poorer. It needs our products. I think, yeah, there's always risks. I worry about cyber, I worry about lots of those things. But I think as we sit here today, this is product by product, disciplined execution, and we don't lose that focus.
Yeah. There's been a bunch of investor interest in some of the BD events over the last week.
I guess there's retinal launch in Europe. I guess in particular, the Enzeevu launch
in the U.S., and I guess private labels. It's sort of a start of maybe a different strategy. Can you talk a little bit about that? I guess there was a press release around that
Yeah
which I guess people found interesting. I think what you can say around that would be useful, just given its timing in the last few days.
Sure. Well, A, it was an ad hoc, so we generally don't do press releases unless it's material. In a sense, it shows the materiality of that deal. There's not much more I can say about the specifics. Is this a strategic shift to do own label? I would say no, but clearly we are flexible and open-minded, and I think have a strong enough capability to manage that on a product-by-product opportunity. Clearly, we were the first to do an own label with adalimumab and then ustekinumab, and now we're doing an own label for aflibercept. I think it's an extremely exciting opportunity. The value really kicks in in the second half of 2027, with strong value carryover to 2028. It has committed volumes, and I think it's a really exciting way of entering this market in a profitable and attractive way.
Yeah. Let's talk a little bit about GLP-1s.
If I can, I guess.
I'm saying nothing.
Kind of a fireside without really touching on that. I guess you launched Owozy, semaglutide, literally within the last 10 days or so.
Yeah.
I guess I'd be curious what the early reads are on that. Also, investors sort of ask what success in Brazil looks like to the company, and I guess how you'd kind of use that, and I guess also in Canada for the wider GLP-1 markets.
Look, I think I've got a picture of the first patient, which is nice. It's too early to say. Look, in Brazil, we have a two-product strategy, so we've launched our first product. We just got our approval now for Sandoz semaglutide INN. If you take a step back, if you look at what's happening both in Canada and in Brazil, I think I've always said this is a supply conversation, not a demand conversation at this point. EMS have supply problems in Brazil. Canada, I think we've had four product recalls so far. This is a complicated product with a device that patients want to build trust around using. I think certainly in Brazil, this has played well to the originator in the short term. This is a longer journey.
This is about the quality of your supply, the quality of your product, the relationship, and the ability to come to the market. So that's probably the most important learning that I've seen at this point. We are still confident that we would look to launch in Canada later this year. We've launched now in Brazil. We will now launch a second brand. It's way too early to sort of say, "Well, this is what I think pricing dynamics look like. This is what volume expansion." I think the market will still be constrained. I think demand will still run ahead of supply, and I think supply has been bumpy to date because of both quality issues, the complexity of this product, and trying to understand the dynamics in terms of what patients actually want.
Perhaps for anyone sort of less familiar with the overall strategy, your longer-term guidance obviously excludes GLP-1s in terms of top line, but where do you see the company sort of participating in the broader opportunity as we get into the earlier part of the next decade?
Look, we're the largest generics company in the world, and we're the largest biosimilars company. We would aspire to have a similar level of execution in GLP-1s. I think we've got great partners. We have a clear strategy. We're also not tied to one molecule. We can bring numerous molecules, combinations, presentations, injectables, orals over the next decade. What we said is, look, we would more than double the value of the sales of the company by 2035, excluding GLPs. I would estimate GLPs is going to be in the billions of dollars, but is that going to be $1 billion or $5 billion or what? It's way too early to say. I know if I put a number here, I'd be spending the whole day trying to justify why I think it's this number.
I think separating those two things out, we were very conscious at the Capital Markets Day not to put a lot of information around GLP-1s because I think it would have distracted the conversation, which comes back to this core opportunity with $600 billion of product coming off patent, a large chunk of biosimilars. We're already the leading biosimilar player. We're extremely well-positioned to capture it. It's an and.
Yeah.
It's a cherry on the cake, but the cake is still very attractive, and let's keep focusing on that.
I guess when we think about the generics business, just mindful of time, I think some investors were surprised at the sort of the reemergence of the penicillin kind of headwind we saw kind of in Q3. We saw it in Q1, less so I think in kind of Q2. So what gives you the confidence that that's behind us?
I guess it cannot get much worse. I mean, being a little bit cynical. Look, the B2B part particularly has been very badly impacted by Chinese dumping. I have used that. Is that material to the business? No. Clearly, I try to use the earnings call and every opportunity to put pressure on governments, particularly European governments, to act. I think it is appalling that as the last remaining penicillin manufacturer left in Europe, we are quibbling over literally cents on a pack to protect an asset. I go to the Pentagon. The U.S. government today buys their antibiotics from China. It is crazy. Everybody agrees with me in the room, but it is like going for dinner, but no one wants to pay. There needs to be a conversation. Rightly or wrongly, I am spending a lot of time pushing that.
I think the base business, the retail business, is pretty stable and consistent. It has been particularly the B2B business, because what has happened is the Chinese have sold into India. Modi put a block on using Chinese API for the domestic market, but the Indian manufacturers are going to use that API to convert and export, particularly using 6-APA. That is pretty much washed out by the end of this year.
Great. Time flies when we are having fun. I think we are-
Thank you
out of time. Thanks so much, Richard.
Thank you.